EGFR and non-small cell lung carcinoma: The therapeutic landscape of non-small cell lung cancer (NSCLC) patients that carry somatic mutations in the tyrosine kinase (TK) domain of epidermal growth factor receptor (EGFR) has been successfully validated during the last two decades and the prolonged survival of those patients who benefit from EGFR TKIs has already proven through numerous clinical studies [1,2,3,4].